<span item_type="fundamental" item_id="a8498be484c2187ec8cad7ce819329e0" counter_id="ST/US/MNMD" env="prod"></span><span item_type="announcement" item_id="544369868416288001" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.5.</p><p></p><h3>Cash Balance</h3><p>Mind Medicine (MindMed) Inc. reported cash, cash equivalents, and investments totaling $237.9 million as of June 30, 2025, compared to $245.5 million as of March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-ex99_1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-ex99_2.htm"></span></p><h3>Research and Development (R&amp;D) Expenses</h3><p>R&amp;D expenses were $29.8 million for the quarter ended June 30, 2025, compared to $14.6 million for the quarter ended June 30, 2024, marking an increase of $15.2 million. This increase was primarily due to $14.5 million related to the MM120 ODT program, $1.5 million in internal personnel costs, and $0.2 million related to preclinical activities, offset by a $1.0 million decrease in MM402 program expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-ex99_1.htm"></span></p><h3>General and Administrative (G&amp;A) Expenses</h3><p>G&amp;A expenses were $11.1 million for the quarter ended June 30, 2025, compared to $9.8 million for the same period in 2024, an increase of $1.3 million, primarily due to increased personnel costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-ex99_1.htm"></span></p><h3>Net Loss</h3><p>Net loss for the quarter ended June 30, 2025, was $42.7 million, compared to $5.9 million for the same period in 2024, a decrease of $36.8 million. This was mainly due to increases in operating expenses of $16.4 million, changes in the fair value of warrants issued in the September 2022 offering of $15.6 million, the absence of a $2.5 million gain on extinguishment of contribution payable from 2024, and increased interest expense related to the amendment of the credit facility of $1.8 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-ex99_1.htm"></span></p><h3>Operating Expenses</h3><p>For the second quarter of 2025, the company reported operating expenses of $40.9 million, with research and development (R&amp;D) expenses amounting to $29.8 million and general and administrative (G&amp;A) expenses totaling $11.1 million.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-ex99_2.htm"></span></p><h3>Credit Facility</h3><p>MindMed has a credit facility of up to $120 million, with $42 million outstanding as of June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-ex99_2.htm"></span></p><h3>Shares Outstanding</h3><p>The company had 75.8 million shares outstanding as of June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-ex99_2.htm"></span></p><h3>Outlook / Guidance</h3><p>MindMed anticipates topline data from the Phase 3 Voyage trial in GAD in the first half of 2026, followed by the Panorama and Emerge trials in the second half of 2026. The company expects its cash, cash equivalents, and investments to fund operations into 2027 and at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-ex99_1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1813814/000095017025100902/mnmd-ex99_2.htm"></span></p>

Mind Medicine MindMed | 8-K: FY2025 Q2 EPS: USD -0.5